:   NSCLC PTR PR

>>2017.04.07 ѱMSD anti-PD-L1 鿪׾ ŰƮ 1ġ ̻ ǹ"  ѱMSD 鿪׾ ŰƮ ==PD-L1 鼭(TPS 50% ̻) EGFR Ǵ ALK ̰ ȯڴ..Ϻ ö "鿪׾ ۿ  "

[޵ĮƮ ȣ ]   鿪׾ ŰƮ Ҽ 1 鿪׾ ۿ  Ⱑ ȴٴ 򰡰 Դ.

Ϻ 系 ö [] ŰƮ Ȯ ڰȸ ̹ 1 ο " ̸, Ƿ ȯڵ 밡 ũ" ߴ.

" 1 5 ̹ "̶ ū 밨 Ÿ´.

׷鼭 "ܼ Ȯ뿡 ġ° ƴ϶ ȯڵ 鿪׾ ۿ  Ⱑ Ǵµ ū ǹ̰ ִ" ٿ.

ʳⰣ EGFR Ǵ ALK ̰ ༺ Ҽ 1 ġῡ ġ ɼ ѵ ־. װ ̷ ȯ Ը ӻ ȿ ߴ. 

̹ 1 ٰŰ ӻ KEYNOTE-024 ŰƮٰ ǥ ׾ȭп 50%[ 0.50(95% CI 0.37~0.68); p<0.001] . 40%[0.60(0.41~0.89)] . 

ڴ ϴ ༺ Ҽ ȯ ġ PD-L1 鼭(TPS 50% ̻) EGFR Ǵ ALK ̰ ȯڿ. 

ۿ ٴ ǹ̿ "Ϻ ȯڴ 3 鿪׾ 纴 ޴ 찡 ִ"鼭 "鿪׾ Ͽ ó޾ƾ Ѵ" ߴ. news@medical-tribune.co.kr  

>>2017.04.11 鿪׾ 'ɵ' 5 16%  

[޵ĮƮ ȣ ]   ༺ Ҽȯڿ anti-PD-L1 鿪׾ ɵ(и Ϻ縿...ѱǰ ѱBMS) 5 ǥƴ. ̱ ϴ ϼ ð(Scott N. Gettinger) ڻ ġִ ༺ Ҽ ȯ(129) ӻ CA209-003 ̱Ͽȸ(AACR) 'Ʈ∙ű ο 鿪׾ ӻ' ǿ ǥߴ. 

ȿ ϴ ̹ ӻ ɵ ġ ȯ 16% 5Ⱓ Ÿ. ð ڻ翡 ݱ ༺ Ҽ ȯڵ 5 5% ̸̾.

ڻ " ֱ ټ ȯڿ ʾҴ"鼭 "̹ ӻ ȯڵ Ⱓ ٽ ִ ߿ " ߴ.

ɵ𺸴 鿪 ǥ ܹ PD-1 ۿϴ anti PD-1 鿪׾̴. 2015 3 20 Ǽ 2 ġ, 2016 4 1 ʷ PD-L1 ο ݱ ȭп ༺ Ǵ ̼ Ҽ ġ BRAFV600E ߻ Ǽ 1 ġ ľó 㰡 ޾Ҵ.


>>17-11-18 ȯ ġ, ǥ׾ ޷ȴ

ʱ⿡ ߰ߵ ̳ 缱 ġ , ٸ ̰ Ͼ 4̳ ׾ ġؾ Ѵ. ׷ ׾ ϼ ƴ϶ пϴ Ǻ, , ׼ ϴ ִ. ‘׾’ ġḦ Ѵٰ ϸ ȯڰ Ż, , ɰ ۿ ø ȴ.

̷ ۿ뿡 ũ ִ ٷ ǥ׾. ǥ׾ ϼ Ǵ Ư ǥ ϱ ۿ ̸鼭 ġ ȿ ȹ ִ.

ǥġ Ư Ǵ (BCR-ABL) ϴ ̸Ƽ(۸)ε ߷ ̽ ؾ ϴ ɰ Ϸ ġ ִ ƴ.

̸Ƽ Ծ ǥġ ߵƴ. ‘Ǽ ü’(EGFR) ̰ ִ ġῡ Ǵ Ƽ·Ƽ·Ƽ, ALK ġῡ Ǵ ũƼ, HER2 缺 ϰ Ͽ Ǵ ƮƮָ, CD20 缺 ġϴ ø ǥ ǥġ.

ܿ MET, ROS1, RET, TRK, FGFR پ ġǥ ǥġ ̸ Ϻδ ӻ󿡼 ̴.

ǥġ  Ͽ ȿ̶ ص Ͽ ƴϴ. κ Ư ġǥ Ǵ 쿡 ȿ̴. EGFR EGFR ڿ ̰ ִ Ͽ ȿ̰, ALK ڰ 缺 Ͽ ȿ . ALK EGFR 缺 Ͽ ȿ . HER2 HER2 缺 ϰ Ͽ ȿ̰ HER2 쿡 ȿ .

ǥġ ϱ ݵ ȯ 翡 ߻ ںȭ Ȯؾ Ѵ. ó 翡 ߻ ںȭ ´ ǥġ ϴ ġ ‘ġ’ Ǵ ‘’(precision medicine) ̶ θ.

׷ٸ ǥġ 4̳ ̾ ġų ? ϰԵ ̳ ϰ ׷ ܰ迡 ̸ٰ ϱ ƴ. ǥġ ༺ ȯ Ⱓ ̻ ִ ǰ , ð ߻ϴ ϱ ƴ. ϳ ġ ϼ ȣ ص ϼ ٸ ȣ θ ãƳ ϱ ̴. ̿ ǥġ غϱ ġ ߵǰ ִ. ֱ ε Ƽ(ALK ), øƼ(EGFR ) ù ° ǥġ ̴ ȯڿ ٽ ġ ȿ ̴ ̴.

ǥġ ׾ ۿ , ׷ٰ ۿ ƴϴ. ׾ ۿ Ż, , 󵵴 پ, ǥġ ۿ ߻ϸ ġ ִ ۿ( 忰, ) ǰ ִ. ǥġ ǥġ ġȿ ۿ뿡 İ ǻ翡 óž ϸ, ġ ġ ۿ ó ִ ϴ Ƿ óǴ ٶϴ.

>>2016.08.01 “EGFR ġ, ̱ ؾ”[ͺ] Ϻ 系 系

Ҽ EGFR, ALK, T790M ǥ׾ ̾ 鿪׾ ġɼ ϸ鼭 ġ ǥ Ⱓ 忡 ǰ ִ. ̷ Ⱓ ȯڰ þ, Ⱓ ٸ ̰ Ͼ ȯ ҷԴ.

߿ ̰ 40% ȯڿԼ Ÿ ˷, ̵ ġ ĸ ̴ ٸ ö. ̸ ݿϵ ‘Ÿ׸’(и øƼ), ‘ī’(и Ƽ) ֱ ߵ Ҽ ǥ׾ ž ǥ׾ ޸ ӻ ̿ ȿ̶ ٰŸ ȮϷ ̰ ִ.

׷ ӻ忡 EGFR 缺 Ҽ ġῡ ‘̷’(и Ƽ), ‘Ÿ’(и Ƽ), ‘Ʈ’(и Ƽ) EGFR ǥ׾ 뼺 ִٴ ð ݴ. ̿ ؼ ̰ Ƿ, ʱ ܺ ̰ ܵ ̸ ʿϴٴ Ϻ Ƿ м̴. ̿ Ϻ 系 (系) ̵ EGFR 缺 Ҽ ġ зӿ ⸦ ô.

- ֱ ̵ ָǰ ִ .

׷. ֱ ½ ȯڵ ϰ ִµ, δ ȯ 20~30% ̰ ִٰ , üδ . ̴ EGFR̳ ALK ǥġ п Ⱓ Ʊ ̴.

4 ȯ κ Ⱓ 1 ѱⰡ ʾ, Ⱓ 2, 3⾿ þ. ׷ٺ ȯڵ Ⱓ 鼭 ̰ þ κе ִ. MRI ϰ 鼭 ã ߴ ̼̱ ߰ ְ ִ.

- ֱ ž ̿ ͸ ̴ .

3 EGFR ǥ׾ ڻ ô ʿ (๰) ִ. ̱ӻȸ ͸ ٴ Ȯεȴ. ٸ 1, 2 ʱ ӻ迡 ô Ȥ ȯ κ Ѵٴ ƽ. ̵ ӻ迡 ܵǴ ȯڿ Ű Ÿ ȿ DZ , ̰ DZ ΰ踦 Ȯϰ Ȯϱ κ ֱ ̴.

̷δ и ̿ ȿ , ȯڸ ӻʹ ʴ. ӻͷδ ־ ϰ ְ, ȯڰ ִ ӻ ġ ȿ ̾ ϴ ٶ̴.

- ǥ׾ ġ .

ʱ⿡ ȯڿԵ ȿ , ʹ ̰ ٽ Ŀ 찡 ִ. ̷ ǥ׾ ġḦ ޴ ȯ ̰ ȯڰ ݴ. ǥ׾ ũⰡ ۾µ, ๰ DZ ̴.

̸ ̰ Ŀ Ƿ ٲ Ѵٰ ߾µ, 򿡴 ġؾ Ѵٴ ִ. ռ ó ǰ ̸ ¦ Ŀ ġ Ⱓ ϴ ȯڰ ִ.

NCCN(̱ վϳƮũ) ̵ο ̰ ¦ Ŀ ġ ϰ Ƽ, Ƽ ġ ϵ ǰϰ ִ. ޿ ɷֱ ġ з ٲ ִ ⿡ ִٰ ִ.

- 1 ǥ׾ ִٰ ΰ.

׷. 1 и ִ. Ϻο 3 ȿ 3 1 ġ ϸ Ĵ ǰ ְ, ׷ ǰ ִ. ׷ ٸ Ϻο 1 鼭 ð , 3 ġⰣ ִ ø ٰ ϴ ǰߵ ִ. δ ڰ, 1 ġ ϴ ٶϴٰ Ѵ. 3 ߻ 1 ȿ Ÿ ֱ ̴.

- Ƽ, Ƽ, Ƽ, EGFR TKI ̿ ̰ ֳ.

迭 ̾ ȿ · иϴ. ߿ ġ ô 󸶳 캸, Ƽ Ƽպٴ . 鿡 Ƽ Ƽպ 2.5 ô 󵵵 Ÿ. ̷ ġᰡ ߿ ȯڵ鿡Դ Ƽ Ƽպ κ ִ. Ƽ Ƽտ Ǻ ۿ ̱ ġ õ ʿϴ.

- ׷ٸ Ƽ ۿ 뷮 ϸ ʳ.

࿡ , ɷ  ̰ Ѵ ϴ ߳󵵳 и Ѵ. ȯڸ Ǻ ̳ ۿ Ÿ 뷮 ̱⵵ ϴµ, 뷮 ٿ 󵵰 ż ȿ ʴ 찡 ִ. ͸ 뷮 ȿ Ȯغ ׷ ʾҴ.

- μ Ͽ Ƽ ȿ̶ ִ ΰ.

EGFR ҼϿ Ƽ Ķ Ƽ ,  2~3 ȿ Ÿ ˷ ִµ, κ ȯڴ. Ƽ Ǻε ֱ , ô 鿡 Ƽպ ٰ . ̰  ׾ ؾ ϴ ʴ.

ô̰ ִ EGFR Ҽ ȯڸ Ƽհ Ƽ ־µ, ô̿ Ƽ ȿ Ÿ. δ ʱ ܿ ô̰ ߰ߵ Ƽ ȣϴ ̴. ô׿ 󵵰 ö ȣǴ ̴.

̿ܿ Ƽ ϴٰ 3Ͽ 1 ϴ 󵵿 ȭ ְų 缱 غ⵵ ߴµ, ȯ ʴ ʾҴ. ٿ ֱ õ ž൵ Ѵٸ ġ ɼ ϰ ִ.

- ȯ ġ ĸ ̱ ʿ .

̰ , 缱 Ǵµ, ʾҴ. ̸ ȮϷ ֵ ӻ ʿ, 䱸 δ ũ. ڰ ִ ͵ ƴϴ.

ֵ ӻ Ȱȭ ϴ ٶ̴. ٴ ȯ , . Ѵϴ ٷο , ̶ Ѵ.

  leejs@docdocdoc.co.kr


>>2017-02-02 KRAS ̴ ġ ==ܱ ̼ , RNA→ġ RNA ȯϴ ‘ġȯ ȿ’ == ‧Ͽ ȿ …ڸڼġȸ 2ȣ ǥ

ܱ ̼ (а) , , Ҽ پ 翡 ȿ پ ġ ߴٰ 2 .  ϼ Ư ġν ġ ʾ а迡 ָ ް ִ. ܱ ġ ׾ ȯڵ ȿ̰ ϰ ġ ϰ ִ. 

̱ ڼġȸ η ·· о ̸ ‘Cell' ڸ 'Molecular Therapy’ 2ȣ ǥƴ. Ȩ ֿ 䰡 Ұƴ.

̼ ġ ٽ ϼ ߵǴ Ư Ư RNA ȯϴ ̴. 

RNA DNA Բ ޿ ϴ ٻ ̴. 

ߵǰ ֿ ߾ ‘ KRAS ’ ̵ Ư ġ RNA ȯ ִ ‘ġȯ ȿ’ ߴ. 

‘ KRAS ’ · ̽ ‘RNA ġȯ ȿ’ ȿ Ű ߴ. ݸ KRAS  ⵵ ġ ʾ ‘RNA ġȯ ȿ’ ü , ȿ ִٴ ߴ.

RNA ġȯ ȿ’ ̵ KRAS RNA ( 'U') Ư ϻ RNA (ʷϻ) ȯŴν, KRAS ڰ ̵ ϼ ׾ ڸ ϵ Ѵ.© News1

̼ “̹ RNA ȿҴ ϴ ϰ ÿ ׾ ׾ Ư̼ ȿ δ” “ ȯ ̵ ڸ ǥ ֵ ġᰡ ϴ” ߴ. 

̹ ̷âк ̿‧Ƿ߻ ߰߿ Ǻ ߻ ƴ.

---------------------------------------------

***ȯ 85% Ҽ̸, Ҽ ټ(75%̻) EGFR̷μ EGFR 缺, 25% KRAS ===> ȯ 40% EGFR缺, 60% ‘EGFR ’ *** ũ Ҽ(SCLC) Ҽ(NSCLC) µ Ҽ ü 85% Ѵ. Ҽ ٽ Ҽ(NSCLC) (SCLC) . () Ҽ() 70~75% κ ϰ () Ҽ 25% ˷ ִ. ȯڰ Ҽ ȯڱ̶ ִ.... 75% EGFR̾缺, 25% KRAS̾缺 Ÿ ִ..  Ҽ ˻縦 EGFR ̰ 缺, ٽ . EGFR缺 EGFR-TKI ̷(Ƽ), Ÿ(Ƽ), Ʈ(Ƽ) ϸ ȴ. EGFR(KRAS缺) , Ǵ 뼼̶ ˸Ÿ Ѵ. EGFR ̰ ƴ Ǽ Ű(ALK) 缺 ڸ(ȭ),  ȵ 쿡 ī(Ƽ), ˷Ƽ(ν), 긮Ƽ(ĸƼý) ϴ ϴ. Ҽ()̸鼭 PD-L1缺̸ ŰƮٳ ɵ 鿪׾ !! ȯ Ȯ мϰ ׿ ´ ġ ϴ ߿ϴٴ ̴.

---------------------------------------------------

** 翡 ũ “Ҽ(small cell lung cancer: 20%))” “Ҽ(non-small cell lung cancer: 80%)” зϸ, Ҽ ٽ “Ǽ=(adenocarcinoma: 40%)”, “Ǽ(squamous cell carcinoma: 30%)”, “뼼(large cell carcinoma: 15%)” ũ մϴ. Ҽ ȯ 15~25% ߻ϸ, Ǽ Ͽ ߰ ٸ  ̵Ǿ ִ 찡 , ַ õǾ ֽϴ. Ҽ ⿡ ܽô ġḦ Ͽ ġ ֽϴ. Ϲ Ҽ Ǽ 谡 ݸ ˷ ֽϴ

** 󿡼 ϰ ٸ ⿡ ̵ Ͽ ½ϴ. (󿡼 ) 帮ڽϴ. 85% Ҽ(NSCLS, non-small cell lung cancer)̰, 12-13% Ҽ, 1-2% ϱ Դϴ. Ҽ ȯڰ 86-87% , Ҽ ū ϰ .

ϼ ũ ¿ ִµ, ̰ , ũⰡ 츦 ‘Ҽ’ ̶ ϰ, 츦 ‘Ҽ’ ̶ մϴ. Ҽ Ǽ, (), 뼼 ̷ 3 ũ ִµ ߻ Ǽ 35%, () 65%, 뼼 4-5% Դϴ. ѱ ణ ϴ.

===˸Ÿ Ǽ(EGFR , 뼼) ȯڿ óմϴ. ˸Ÿ ýöƾ Ͽ ϴµ 3⳪ 4 ȯ. , Ұϰ ġ ġḦ ȯڵ鿡 Ⱓ óϰ ֽϴ.

3 ϴ ȯڵ鿡Դ ˸Ÿ ξ ๰(Ź+ýöƾ) óմϴ. ׾ȿ شȭ Ű ؼ. ׷ ˸Ÿ ๰μ óմϴ. Ư, EGFR ̰ Ͼ ȯڵ鿡 óմϴ.

==EGFR(Ǽ ü, Epidermal Growth Factor Receptor) Ǽ ڷ, ̰ Ͼ , ߻մϴ. EGFR ̷ ߻, EGFR 缺 ȯڵ鿡Դ EGFR ƽƮī  '̷(и : Ƽ)' ν 'Ÿ(и : Ƽ)' óմϴ.

̱վϳƮũ(NCCN, National Comprehensive Cancer Network) ̵ο EGFR 缺 ȯڵ鿡Դ 1 ġ EGFR (̷, Ÿ) ϵ ǰϰ ֽϴ. EGFR ȯڵ鿡Դ ˸Ÿ + ýöƾ ó մϴ.

ֱ, 40-50 ڿԼ ̰ ߻ϴ 찡 ð ֽϴ. ߻ Ȯ ʾ, ָ EGFR̿ ߻ 翡 ƽþ(ѱ, Ϻ, ߱, 븸 ) 3 ̻ Դϴ.

Q. ˸Ÿ 뷮  ˴ϱ?

Ұ ȯڸ óմϴ. ˸Ÿ Ǽ(, 뼼) ȯڿ óմϴ. ˸Ÿ ýöƾ Ͽ ϴµ 3⳪ 4 ȯ. , Ұϰ ġ ġḦ ȯڵ鿡 Ⱓ 1 óϰ ֽϴ.

˸Ÿ 500mg ϴµ ܵ, տ մϴ. 츮 ޿ ؿ , 1 ġμ ýöƾ Բ մϴ. 2 ġ 1 ȭп ̻ ȯڵ鿡 ˸Ÿ ܵ մϴ.

Q. ǻ ?

˸Ÿ ۿ ؼ, 䳪 Ż, ġ ſ ̾մϴ. Ǻ ణ ˰ ϰų ֽϴ. Ÿ B12 Ѵٴ Դϴ. ϸ, Ÿ B12 ֻ縦 մϴ.

, ũƾ ġ ̻ ȯڵ鿡Դ AUC (๰, area under the plasma level-time curve ; ๰ ü ) ũ Ÿϴ. , ɿ ˸Ÿ ؾ մϴ.

Q. ˸Ÿ ۿ ΰ? 

ϰ ϸ, ˸Ÿ DNA ռ ϴ 3 ȿ(TS, DHFR, GARFT ȿ) Ͽ ϴ Դϴ. TS Thymidylate synthase, DHFR Dihydrofolate reductase, GARFT Glycinamide ribonucleotide formyltransferase Īϴ Դϴ. DHFR ٷ reduction Ű ȿε, Բ ؾ ϴ ٷ ˸Ÿ ȿҸ ϱ .

Q. ˸Ÿ ֿ ӻ  ֳ?

Ķ󸶿Ʈ(PARAMOUNT) ӻ , ˸Ÿ ýöƾ 1 ġḦ , ˸Ÿ ܵ (ġ), Ⱓ Ǿϴ.  ,  ũⰡ پ ƴ ϰ Բ ϴ Ⱓ þٰ . Maintenance ٷ װԴϴ.

Q. ˸Ÿ ü ?

˸Ÿ Ư㰡 2015 5 Ǿ, ο ׸ ǰ Դϴ. ׷ ׾ ׸ ǰ ϴ Ϳ Ȯ ʿϴٰ մϴ. ǰ ϰ, ׾ ȯڿ ‘’ , ȯڵ 迡 ϰ ϴ ͵ ƴ϶ մϴ. ‘ü’ ɼ ׿. 


>>17-11-15 Ư ͷ ã ݵ = Ư ..., м 'PTR'...ֽ Ѿ Ư㰡ġ ... ġ ...ݵ … ׷ ָ
==“ Ư㰡ġ ǥ Ȱϸ ?” ϳ ̵. Ư㰡ġ  ۳ ݱ⼼ ߿ Ѵ. Ưȣ Էϰ Ű ϳ ġ Ư㰡 ¥ ߻ ִ ̴ַ. ȸ ⼭ ѹ ư.
Ư㰡ġ ְ غ ̴. Ư㰡ġ ְ ϼ ְ· ٴ ߴ.  ̴ ǻ縦 ãư, 6 ݵ带 ϱ ߴ. ְ(PTR:Price Technology Ratio) ڶ ۵ ̴. ǰ  27 ȸ ‘ũ ’ ޸ ذ(MOU) üϰ 1Ϻ 6 PTR ݵ带 Ѵٰ .
ݵ ڱ ڵ ƴ ڱں̴. ȸ ׽Ʈ غڴٴ . ڴ “Ȯ ݾ ʾ ”̶ “6 غ ǥ Ϲ ǰ ߿ Ȱ ȹ”̶ .
PTR ֽĽ忡 ðѾ Ǹȭ Ư㰡ġ Ѵ. PTR 򰡵ư, PTR 򰡵ƴ ִ. 26 LGڴ 1.58 ݸ Zڴ 4.27 ̴. ¸ LG ְ ()̶ ؼ ϴ.
PTR̶ ʴ. ǥδ ְͺ(PER) ְڻ(PBR) ַ Ȱƴ. PER ְ ִ(EPS) Ϳ ְ ϴ ǥ ǥ Ȱǰ ִ.
==27 α ׶£ 2 ũ 翡 () ǥ ̻ ϼ  ǥ̻簡 ذ(MOU) ü Ǽ ϰ ִ. ѱ bwh3140@hk.co.kr
PTR ־ 濡  ߿ ‘IPͷκ’̶ ű ־. κ Ưȣ Էϸ ڵ Ư ġ Ѵ. 15Ⱓ 18,000 Ư ͸ 򰡿 Ȯ . ۳ Ư㰡ġ Zڷ Ѿ 63,223 Ѵ.
ϱ  ǥ “PTR 2010 5 ְ غ PTR 2.5 ְ· ٴ ǹ Դ” “ ǥ Ȱ ִٰ ȸ翡 ”̶ ߴ.
̷ ָ ٷ ڸ ߴ. ڴ “ ġ ϴ ǹ ִ ǥ ִٰ ô” ߴ.
ʴ Ȱ ο ǰ ´ٴ (financial) (technique) ռ ũ(fintech) ϴ ̶ 򰡸 ް ִ. ʹ ũ ٽ̸ ΰġ Ȱ뵵 о߷ ָ ް ֱ ̴. ̳ 翡 “ũ ü Ȱ پ о߷ Ȯǰ ִ”“ε پ о ũ 񽺸 ǻȰ ü ֵ ”̶ ߴ. ȯ redsun@hk.co.k

[[Ư ġ 尡ġ ȭ ]]

file:///C:/Users/Home/Downloads/7.+%EC%9D%B4%EC%84%B1%EC%83%81+%EC%99%B8.pdf


%% Ư ġ ϱ 濵 ں ġ ϰ, ں ϴ Ư ġ Ͽ. ̷  [Ϲȭ Ư ġ] Ư Ư Ÿ Ư , Ư , Ư Ʈ Ȱ, Ư Ʈ ݿϿ  [Ư ġ] Ͽ((##Ϲȭ Ư㰡ġ*1.3=Ư㰡ġ)).....


===>Ư ġ  Ư ġ ġ(ð Ѿ) Ͽ...... (Ư̶ !!) ϰ, 18 ġ ȭ , Ͽ. м Ư ġ 尡ġ Ҵ 尡ġ ܿ ſ Ҵٴ Ȯ ־. ((̰ Ư ڽ/ڽ ϶ ϴ µ...Ư Ư<3 ϶  1, 1.5 ְ 45%̻󿡼 Ǿ ſ )). Ư ġ Ư 尡ġ ȭ ġ ȿ ȸͺм Ư ġ 尡ġ Ư ġ 12, 18 尡ġ ִ Ÿ 

***((Ϲȭ Ư㰡ġ)) 1.3 ǰ꿡 ̴ Ư㰡ġ ...

***Ư㰡ġ 尡ġ ϴ κ ,  尡ġ() Ư㰡ġ ִ 15 ̳ 򰡷 ...(( Ư㰡ġ 10̳..., Ȳ Ƶ  10%̻ ׻ ְ Ѵٰ ::: 3̳  46% ְ ־..))

==Ư㰡ġ 尡ġ (<3) 1.5⳻ ġ ȹ

....> PR 1400尡ġ(ְ3500.4õ)...ϹƯ㰡ġ 6õ (׷ Ư㰡ġ7800)... 0.18 򰡻((4õ 6... 65, 228260 ġ ==>1ַ ڽ ̸ Ư 6.5 5, 10 78000))  

%%Ư ְ 򰡵 ϴ ˰ ڸ κ  ͷ ޼.

>>2015.06.10 "ִ ֽ ã"···PTR(ְ) ƽó....̹ б Ҵ Ư㸦 Ʈ ÷Ƚϴ. ڸ ޵ Ͻ ÷ ." 
̱ (IT) ù ° ° ִ ù. ش ó ֿ ϵ Ư  ȭ ͵ л鿡 ҴѴ. л Ư㸦  ĿӼȶ¡(ȭ) ΰ Ͻ ÷ , Ư㸦 ڵ , ڵ ãƼ ݵ ¡ Ѵ.
󸶳 ϰ SWOT(··ȸ·) м ߳, ڿ ܰ躰 Ī 󸶳 ְ ߳ 򰡹޾ ޴´. ̸ ŸƮ Ưȭ óȸ, Ƿʸ ̱ (business law) Ѵ. 
̿ ѱ IT . п о ַϸ鼭 ۼ ϴ 찡 . ̷а ġ ⿡ ٻڰ 帧 ణ ϴ ʰ . 
Ư㸦 ߴİ ƴ϶ İ ǥ ̴. Ư ü ̶ ϱ ƴ. Ư㸸ŭ 뺯 ִ ǥ ̴. Ư㸦 , Ư  (ġ ִ) Ư㸦 ִ ̶ ִ. 
̷ Ȳ ֱ Ư ġ  PTR ִ. 
PTR(Price Technology Ratio·ְ) ðѾ ǥ.  Ưȣ ġ ¥ ġ , Ҽ ɷ Ưȣ Էϸ Ҽۿ ִ ڷḦ ڵ ַ ϰ ִ. 
˰ Ư ġ Ѿװ PTR ߴ. (PTR=ְ/ִġ) PTR ٸ(2.5) Ư ġ ְ 򰡵 ִٴ ̴. 
ǥ̻() ϼ  ǥ̻() ޸ ΰ Կ ϰ ִ. /ŰDB
 "Ư ͷ ġ ϴ ַ ߴ ְ͵ ǹ ִ ü Դ" ߴ. 
ȸ ǰ ݵ带 PTR ϰ ִ. PTR ڽ ü · ְ · ִٰ Ѵ. ڰ PTR 鿡 ڸ øٸ Ư㸦 ڱ ְ ǰ, ó ° ȯ ⿩ ְ ȴ. ̳ ǰ Ʈũ ص ִ. 
PTR θ ̸ Ͻ 丮 ְ ǰ ڸ â⿡ ⿩ ̴. ݵ带 ϴ ̳ Ȳ â ȣ ġ⺸ٴ PTR . [ Ϻ] 
>>, м 'PTR'//ֽ Ѿ Ư㰡ġ ġ ...ݵ … ׷ ָ//“ Ư㰡ġ ǥ Ȱϸ ?”
ϳ ̵. Ư㰡ġ  ۳ ݱ ߿ Ѵ. Ưȣ Էϰ Ű ϳ ġ Ư㰡 ¥ ߻ ִ ̴ַ. ȸ ⼭ ѹ ư.
Ư㰡ġ ְ غ ̴. Ư㰡ġ ְ ϼ ְ· ٴ ߴ.  ̴ ǻ縦 ãư, 6 ݵ带 ϱ ߴ. ְ(PTR:Price Technology Ratio) ڶ ۵ ̴. ǰ  27 ȸ ‘ũ ’ ޸ ذ(MOU) üϰ 1Ϻ 6 PTR ݵ带 Ѵٰ . ݵ ڱ ڵ ƴ ڱں̴. ȸ ׽Ʈ غڴٴ . ڴ “Ȯ ݾ ʾ ”̶ “6 غ ǥ
Ϲ ǰ ߿ Ȱ ȹ”̶ .
PTR ֽĽ忡 ðѾ Ǹȭ Ư㰡ġ Ѵ. PTR 򰡵ư, PTR 򰡵ƴ ִ.  20155 26 LGڴ 1.58 ݸ Zڴ 4.27 ̴. ¸ LG ְ ()̶ ؼ ϴ.
PTR̶ ʴ. ǥδ ְͺ(PER) ְڻ(PBR) ַ Ȱƴ. PER ְ ִ(EPS) Ϳ ְ ϴ´ǥ ǥ Ȱǰ ִ.
==2017. 11. 13. ѱϺ : Ư ͷ ã ݵ
27 α ׶£ 2 ũ 翡 () ǥ ̻ ϼ  ǥ̻簡 ذ(MOU) ü Ǽ ϰ ִ. ѱ bwh3140@hk.co.kr
PTR ־ 濡  ߿ ‘IPͷκ’̶ ű ־. κ Ưȣ Էϸ ڵ Ư ġ Ѵ. 15Ⱓ 18,000 Ư ͸ 򰡿 Ȯ . ۳ Ư㰡ġ Zڷ Ѿ 63,223 Ѵ.
ϱ  ǥ “PTR 2010 5 ְ غ  PTR 2.5 ְ· (̰ Ǵܱ!!!) ǹ Դ” “ ǥ Ȱ ִٰ ȸ翡 ”̶ ߴ.
̷ ָ ٷ ڸ ߴ. ڴ “ ġ ϴ ǹ ִ ǥ ִٰ ô” ߴ.
ʴ Ȱ ο ǰ ´ٴ (financial) (technique) ռ ũ(fintech) ϴ ̶ 򰡸 ް ִ. ʹ ũ ٽ̸ ΰġ Ȱ뵵 о߷ ָ ް ֱ ̴. ̳ 翡 “ũ ü Ȱ پ о߷ Ȯǰ ִ” “ε پ о ũ 񽺸 ǻȰ ü ֵ ”̶ ߴ. <Ѱ-ȯ >

**>>17-11-15 򰡴 ƴ ٷδ ̷ ġ ϴ ŷ ˰ ֽϴ....𰡸 ϴµ ̷尡ġ ʴ´ٸ ̺˰ ū ȸ ̺ ֹ  Ŀ ߾ õ ø ̴ϴ

,   ϴ װ ڷ ̷ ߱ ȭ̿ ׸  .... ̱ ....Ļ  ǰ ν ԰ݱα ߵ ֵ ԰ȭ Ϸ մϴ... ۷ιڵ忡 ̹   1cm ȵǴ ڱ ڵⰡ ڵ 忡 170޷ ǸŵǾٰ մϴ.... ׷, 170޷ ݾ׸ ܿ Ը 1% ̸̶ ϰֽϴ.... δ 50cm ӵ 2質 ϰ... 9mŸ Ϲ ϱ ... 谡 ָϰ ָϴ ƴұ ˴ϴ

絵 ִԵ ñ⿡, ּ ߱常̶ ڵ ǰ ̷ ̷ġ , Ͽ Ϸ ϰ ִ Դϴ.......߱忡 ڵ 2018 1~3߿ ǰǾ Դϴ. ׶ ߿ ֽİġ ʹ踦 ȸ  Դϴ... ݸ γ Ѻ ֽʽÿ...׸, ֶ ޾Ƽ ٽ ְ ȸ ϰ ֽ Ȯ Դϴ... ̹ Ե Ϻδ 縦 湮Ͽ ޾ ߰ е ð.... ֽ żϽ е鲲 ؿ ǥ ߾ ⿡ ڵ 忡 ڱ ڵⳳǰ Ѵٰ Ȱ.... 5000Ŀ 38 ǸϽô ֺв 7000 28.....38 ֽ 鿴, Ϻ Բ Ǹ 帮⵵ ߾ϴ. ... ε 5 Ȯϰ ֽϴ((̷µ, ϳ 鵵 ׷ ϰ ֽϴ!!))

, ư Ϻȸ ȸ絵 ϰ ߱ ȸ縦 մϴ.. 10̳ 츮 ְ ϳ ϰ Ǹ 󹫴 Ȯմϴ...մϴ... ñ ø ð ڷ ð ãƺƵ ϰڽϴ

*** TSR(Techno Systems Research) ۼ 2019 201700޷( 23000) þ

ĺ ۷ι Ը ڱ 2015 16 ޷ 60.5% Ͽ 2020⿡ 170 ޷(ڱ+ڱ) Ը ȴ. δ ƽþ/ 62.9% Ͽ 2017 17 ޷( 42.5%) Ը ȴ. Ը 2015 24,200 ޷ 60.7% Ͽ 2020⿡ 26 ޷ Ը ȴ((߿ ۷ιڱ 2018 60%(4), 2019 70%(5.5), 2020⿡ 75%(7) ȸ ))....*****[۷ι ] 2017 5.56 <5.563BD> ~2022 15.85 <15.856 BD>( CAGR <19.29%>)  ::::: 2018 6.6<6.6325BD> ==>2019 7.9 <7.9119BD>==>2020  9.4<9.4381BD>==>2021 11.2<11.2587BD>

***ڱ  

• 2015 553鸸 ޷ 2017 1,070鸸 ޷, 20192,017鸸 ޷

• ۽ź Ը 2013 66鸸 ޷ 2017 567鸸 ޷, 2019 1,037鸸 ޷

====>>2020 ޴ 170 ޷Ը

忡 Ǿ ȸ ִ Z ޴ ڱ μ е忡 1cm ų Ȩ ʰų ̽ ä е忡 ÷ ȵǴ 뵵ѵ ̴. Ŀۺ ڱ ̽ ä һӸƴ϶ е忡 cm ־ ̰ ̸ ߱޴Ͽ ڱ Ŀۺ Ǹ ڱ üҰ̴. ȭ ̰ ̽ ϴ Ծ ٷ е忷 α⸸ϸ DZ⶧̴. Ǹ Ŀۺ ̷尡ɼ ʴ°

: ý,..պ..ձ..ü
: λ mrm-ms